Sai Life Sciences Unveils Dedicated Veterinary API Production Facility In Bidar, Marking A New Frontier

Sai Life Sciences, a leading contract research, development, and manufacturing organisation (CRDMO), has announced the opening of Unit VI, a state-of-the-art dedicated facility for veterinary active pharmaceutical ingredient (API) production located at its flagship Bidar site in India. This strategic advancement elevates Sai Life Sciences’ capabilities in the veterinary pharmaceutical sector, complementing its robust human API manufacturing expertise.

Key Highlights Of The Veterinary API Facility Launch

Unit VI is a purpose-built facility solely focused on manufacturing veterinary APIs, situated alongside Sai Life Sciences’ flagship Unit IV manufacturing site, which produces APIs for the human pharmaceutical market.

The new facility establishes Sai Life Sciences as a specialist global manufacturer catering to the rising demands of the veterinary pharmaceutical industry.

This expansion aligns with the company’s vision to diversify its portfolio, serve niche markets, and capitalize on emerging opportunities within animal healthcare.

Sai Life Sciences leverages its extensive cGMP-compliant infrastructure, advanced technology platforms, and stringent quality controls to ensure the facility meets global regulatory standards for veterinary pharmaceuticals.

Strategic Importance Of The Veterinary API Facility

Veterinary pharmaceuticals represent a growing segment driven by increasing livestock productivity needs, rising pet ownership, and enhanced focus on animal health across global markets. The dedicated veterinary API facility at Bidar positions Sai Life Sciences to:

Provide manufacturers of animal health drugs with high-quality, reliable active ingredients tailored for veterinary use.

Address specialized production requirements distinct from human pharmaceuticals, including formulation variations and regulatory parameters.

Strengthen its competitive edge by offering comprehensive integrated solutions spanning discovery, development, and commercial API manufacturing for veterinary clients.

Technological And Compliance Features

Unit VI is designed with cutting-edge manufacturing technologies and containment systems to handle a wide range of veterinary APIs, including complex molecules with high-potency considerations. The facility features:

Advanced clean room environments adhering to ISO standards specific to veterinary API production.

Comprehensive quality control labs equipped for rigorous analytical testing in compliance with international pharmacopeial requirements.

Robust safety protocols and environmental sustainability practices ensuring minimal ecological footprint.

About Sai Life Sciences’ Bidar Hub And Global Presence

The Bidar campus is Sai Life Sciences’ flagship manufacturing site with multiple dedicated production blocks totaling approximately 700 kiloliters of reactor capacity. It caters primarily to international markets such as the US, EU, and Japan, meeting all stringent quality and regulatory requirements including USFDA, PMDA (Japan), and CDSCO (India) approvals.

Serving over 300 global innovator pharmaceuticals and biotech companies, Sai Life Sciences has evolved into a trusted partner for accelerating small molecule drug development from discovery through to commercial manufacturing.

Leadership Perspective

Krishna Kanumuri, CEO and Managing Director of Sai Life Sciences, highlighted the facility’s significance: “The launch of our dedicated veterinary API manufacturing unit signifies a new chapter in expanding our capabilities to meet the evolving needs of animal healthcare. This facility enhances our ability to deliver differentiated solutions while upholding the highest standards of quality and compliance.”

Industry Outlook And Future Directions

With growing emphasis on animal welfare and food security, demand for veterinary pharmaceuticals is anticipated to expand strongly worldwide. Sai Life Sciences’ capacity and expertise enable it to support this growth by providing superior quality APIs that contribute to safer and more effective veterinary medications.

The dedicated facility also strengthens local manufacturing capabilities in India, offering global companies a strategic sourcing partner aligned with their quality and regulatory expectations.

In conclusion, Sai Life Sciences’ inauguration of the veterinary API facility at Bidar marks a milestone that diversifies its service offerings, supports the expanding animal health sector, and reinforces its position as a global CRDMO leader.

Source: Sai Life Sciences official announcements, Business Upturn, GlobeNewswire